Agilent Appoints NIMGenetics as Spain’s First Certified Service Provider for CGH and CGH/SNP Microarrays
News May 19, 2011
Agilent Technologies, Inc. has announced that NIMGenetics S.L. of Madrid has achieved Certified Service Provider (CSP) status for genomic research using Agilent SurePrint comparative genomic hybridization (CGH) and CGH/SNP microarrays.
“We are very proud to become the first Agilent CSP in Spain,” said Dr. Juan Cruz Cigudosa, NIMGenetics chief scientific officer.
Cigudosa continued, “We offer personalized customer service for research professionals that helps them with the design and selection of the most appropriate platform, up to a complete bioinformatics analysis, working with arrayCGH, gene expression arrays and microRNA platforms. NIMGenetics provides services in Spain and worldwide, offering the best products to improve characterization reliability.”
“We’re very pleased to welcome this esteemed organization to our growing team of CSPs,” said Robert Schueren, Agilent vice president and general manager, Genomics. “NIMGenetics has a history of innovation and quality in investigating the effects of alterations in DNA copy numbers, and it’s gratifying to see Agilent CGH tools performing a substantial role in this work.”
“We have been collaborating for years with NIMGenetics and their associated academic partners,” added Pascal Le Floch-Riché, Agilent Southern Europe genomics sales manager. “Their advanced team specializes in the development of genetic research and, supported by our leading array technology, has been accredited by the Spanish Association of Human Genetics.”
NIMGenetics became the first Agilent CSP in Spain after completing training and passing a rigorous series of assessments that included demonstrating proficiency in the complete Agilent integrated microarray workflow: Agilent CGH and CGH/SNP microarrays, sample labeling, hybridization, scanning on the Agilent DNA microarray scanner with feature extraction software, data analysis using GeneSpring and/or Agilent Genomic Workbench software, and sample quality control on the Agilent 2100 Bioanalyzer.
Agilent offers the industry’s only CGH and CGH/SNP microarrays in a wide range of formats, which customers can custom-design at no cost using Agilent’s eArray online tool.
Options range from a single array containing 1 million features through eight individual arrays on a standard 1-in. x 3-in. wafer. The company also manufactures genome-wide CGH arrays for human, mouse, rat and other model organisms.
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.READ MORE
In a study of mice and human brain tumors researchers searched for new treatments by exploring the reasons why some patients with gliomas live remarkably longer than others. The results suggested that certain patients’ tumor cells are less aggressive and much better at repairing DNA than others but are difficult to kill with radiation.READ MORE